Abstracts tagged "Immunoglobulin (IG)"

Abstract Number: 1715 • 2016 ACR/ARHP Annual Meeting
ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A, Does Not Provide Significantly Greater Efficacy Compared with Adalimumab in Subjects with Psoriatic Arthritis: Results from Exposure-Response Analyses
Ben Klunder¹, Amit Khatri², Mukul Minocha³, Paul Peloso⁴ and Ahmed A. Othman², ¹AbbVie, Ludwigshafen am Rhein, Germany, ²AbbVie Inc., North Chicago, IL, ³Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Drugs individually neutralizing TNFα or IL-17…
Abstract Number: 2329 • 2016 ACR/ARHP Annual Meeting
Intravenous Immunoglobulins in the Treatment of Idiophatic Inflammatory Myopathies: Where Do We Stand?
Simone Barsotti^1,2, Elisa Cioffi¹, Alessandra Tripoli¹, Emanuele Calabresi¹, Antonio Gaetano Tavoni³, Anna d'Ascanio¹, Rossella Neri⁴ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²University of Siena, Department of Medical Biotechnologies, Siena, Italy, ³Immunoallergology Unit, University of Pisa, Pisa, Italy, ⁴Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: several data are available about the use of IvIg in the treatment of idiopathic inflammatory myopathies (IIM), but the results derive from small cohorts.…
Abstract Number: 2844 • 2016 ACR/ARHP Annual Meeting
Immunoglobulins Level and Risk of Infection in Systemic Lupus Erythematosus
Ibrahim Almaghlouth¹, Jiandong Su², Dafna D Gladman³ and Murray Urowitz⁴, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patients with SLE have been followed prospectively at 2-6 month intervals according to a standard protocol, which includes detailed clinical and laboratory assessments including…
Abstract Number: 3165 • 2016 ACR/ARHP Annual Meeting
HLA-B27 Expression Is Accompanied By a Profoundly Altered IgA Response to the Intestinal Microbiota and Microbial Translocation to the Joint
Mark Asquith¹, Sean Davin¹, Patrick Stauffer¹, Claire Mitchell² and James T. Rosenbaum¹, ¹Oregon Health & Science University, Portland, OR, ²Division of Arthritis and Rheumatology, Oregon Health & Science University, Portland, OR
Background/Purpose: HLA-B27 is the strongest known genetic risk factor for ankylosing spondylitis and other spondyloarthropathies (SpAs). We have shown previously that Fisher 344 rats that…
Abstract Number: 469 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study
Andrea Cuervo¹, M. Victoria Hernández¹, Sonia Cabrera¹, Jose Inciarte-Mundo¹, Julio Ramirez¹, Virginia Ruiz-Esquide¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Rituximab (RTX) is a biologic therapy approved for the treatment of active rheumatoid arthritis (RA) refractory to tumour necrosis factor antagonists. It causes B…
Abstract Number: 2639 • 2013 ACR/ARHP Annual Meeting
Long-Term Outcome of Monoclonal (type 1) Cryoglobulinemia
Antoine Néel¹, François Perrin¹, Olivier Decaux², Thomas Dejoie³, Maxime Halliez³, Béatrice Mahé⁴, Thierry Lamy⁵, Fadi Fakhouri⁶, Patrick Jego², Christian Agard¹, Cécile Vigneau⁷, Lucienne Guenet⁸, Bernard Grosbois⁹, Philippe Moreau⁴ and Mohamed Hamidou¹, ¹Internal Medicine Department, Nantes University Hospital, Nantes, France, ²Department of Internal Medicine, Rennes University Hospital, Rennes, France, ³Biochemistry Laboratory, Nantes University Hospital, Nantes, France, ⁴Hematology, Nantes University Hospital, Nantes, France, ⁵Hematology, Rennes University Hospital, Rennes, France, ⁶Nephrology, Nantes University Hospital, Nantes, France, ⁷Nephrology, Rennes University Hospital, Rennes, France, ⁸Biochemistry Laboratory, Rennes University Hospital, Rennes, France, ⁹Internal Medicine Department, Rennes University Hospital, Rennes, France
Background/Purpose: To investigate long-term outcome of symptomatic type 1 cryoglobulinemia and its determinants. Methods: Retrospective analysis of a prospective cohort from 2 French university hospitals.…
Abstract Number: 2342 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety Of Rituximab: Pooled Analysis Of The Rheumatoid Arthritis Global Clinical Trial Program Over 11 Years
Ronald van Vollenhoven¹, Paul Emery^2,3, Clifton O. Bingham III⁴, Edward Keystone⁵, Roy Fleischmann⁶, Daniel Furst⁷, Eva W. Hessey⁸, Abdul Mehbob⁸ and Patricia B. Lehane⁹, ¹Karolinska Institute, Stockholm, Sweden, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Texas Southwestern Medical Center, Dallas, TX, ⁷Medicine, University of California, Los Angeles, Los Angeles, CA, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁹Roche Products Ltd, Welwyn Garden City, United Kingdom
Background/Purpose: This analysis evaluated the long-term safety of rituximab (RTX) in rheumatoid arthritis (RA) patients in a global clinical trial program. Methods: Pooled observed case…
Abstract Number: 1892 • 2013 ACR/ARHP Annual Meeting
High-Throughput Immunoglobulin G Fab Glycosylation Profiling Reveals Differential Glycosylation On Fab and Fc
Albert Bondt^1,2, Yoann Rombouts³, Maurice H.J. Selman¹, Radboud JEM Dolhain⁴ and Manfred Wuhrer¹, ¹Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Rheumatoid arthritis is known to improve during pregnancy, and a flare of disease activity is observed after delivery (1). N-glycosylation of the constant region…
Abstract Number: 1336 • 2012 ACR/ARHP Annual Meeting
Changes in the Levels of Anti-Cyclic Citrullinated Protein Antibody and Immunoglobulins in Rheumatoid Arthritis Patients After Administration of Tocilizumab
Masao Sato¹, Masao Takemura², Ryuki Shinohe³, Tsuneo Watanabe² and Katsuji Shimizu³, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Orthopaedic Surgery, Gifu University, Gifu, Japan
Background/Purpose: The recently established scoring system of American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) early arthritis diagnosis criteria have assigned scores of 0, 1,…
Abstract Number: 1176 • 2012 ACR/ARHP Annual Meeting
Galactosylation, and Not Sialylation, of Immunoglobulin G Is Associated with Improvement of Rheumatoid Arthritis During Pregnancy
Albert Bondt¹, Maurice H.J. Selman², André M. Deelder³, Johanna M.W. Hazes¹, Manfred Wuhrer² and Radboud J.E.M. Dolhain¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands, ³Biomolecular Mass Spectrometry Unit, Department of Parasitology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is known to improve during pregnancy and to flare after delivery [1]. Changes in the glycosylation of immunoglobulin G’s fragment crystallizable…
Abstract Number: 2262 • 2012 ACR/ARHP Annual Meeting
Hypogammaglobulinemia in Pediatric Systemic Lupus Erythematosus
Emilina Lim¹ and Megan A. Cooper², ¹Pediatric Rheumatology, Washington University in Saint Louis- St. Louis Children's Hospital, St. Louis, MO, ²Pediatrics, Washington University School of Medicine, St. Louis, MO
Background/Purpose: : Systemic lupus erythematosus (SLE) is characterized by B cell activation, elevated serum IgG and prominent circulating immune complexes. However, hypogammaglobulinemia in SLE patients…
Abstract Number: 1920 • 2012 ACR/ARHP Annual Meeting
Spectrum of IgG4-Related Disease and Diagnostic Value of Serum IgG4 Determinations
Emma Kotisalmi¹, Tom Pettersson², Aaro Miettinen³, Johanna Arola⁴ and Martti Färkkilä⁵, ¹Department of Medicine, University of Helsinki, Helsinki, Finland, ²Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland, ³Department of Immunology, Huslab, Helsinki, Finland, ⁴Department of Pathology, University of Helsinki and Huslab, Helsinki, Finland, ⁵Department of Gastroenterology, Helsinki University Central Hospital, Helsinki, Finland
Background/Purpose: IgG4-related disease is a recently described systemic inflammatory and fibrosing condition that may mimic various other systemic rheumatic diseases. We studied the occurrence of…
Abstract Number: 1921 • 2012 ACR/ARHP Annual Meeting
Diagnostic Utility of Serum IgG4 in IgG4-Related Disease
Mollie Carruthers¹, Tamara Augustin², John H. Stone¹ and Arezou Khosroshahi¹, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Internal Medicine, Internal Medicine, Northshore Medical Center, Salem, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a recently recognized fibro-inflammatory disease with multi-organ system involvement, often but not always characterized by elevated serum IgG4 concentrations. The…
Abstract Number: 1768 • 2012 ACR/ARHP Annual Meeting
The Absolute Concentration of Anti Citrullinated Protein Antibodies in Serum and Synovial Fluid in Relation to Total Immunoglobulin-Concentrations
Annemiek Willemze, Jing Shi, Marlies Mulder, Gerrie Stoeken-Rijsbergen, Tom W. J. Huizinga, René E. M. Toes and Leendert A. Trouw, Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPA) is one of the most predictive factors for the development of rheumatoid arthritis (RA). Nonetheless, relatively little…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].